ClinicalTrials.gg
CompletedNCT06588283TOGETHER-PsOUpdated Jun 17, 2026

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

A Phase 3 interventional study of Ixekizumab and Tirzepatide in Psoriasis and Obesity, sponsored by Eli Lilly and Company. Completed at 72 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
281
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Psoriasis by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Eli Lilly and Company.

Enrollment
10th of 36
281 · median 181
Started
2024
with 1 other
Phase 3
15 of 36
none open now
Registered
33rd of 36
by date

Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 10th largest by enrollment, is one of 2 that started in 2024, is one of 15 in phase 3, and was the 33rd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 36 studies in Psoriasis by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Psoriasis by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab.

Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.

03

Conditions studied

  • Psoriasis
  • Obesity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of moderate-to-severe plaque psoriasis (PsO) for at least 6 months.
  • Have both a Static Physician's Global Assessment (sPGA) score of ≥3 and a Psoriasis Area and Severity Index (PASI) ≥12.
  • Have ≥10% body surface area (BSA) involvement.
  • Have obesity, of ≥30 kilograms per meter squared (BMI ≥30 kg/m²) or overweight (BMI ≥27 to \<30 kg/m²) in the presence of at least 1 of these weight-related comorbid conditions (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or T2DM).

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  • Have Type 1 Diabetes Mellitus (T1DM).
  • Have insulin-treated Type 2 Diabetes Mellitus (T2DM).
  • Have a prior or planned surgical treatment for obesity.
  • Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2.
  • Have active, or a history of inflammatory bowel disease (Crohn's or ulcerative colitis).
  • Have a diagnosis or history of malignant disease within the 5 years prior to randomization, with the following exceptions:

    • basal cell or squamous epithelial carcinomas of the skin that have been resected, with no evidence of disease for 3 years.
    • cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to randomization.
  • Have serious disorder or illness other than PsO.
  • Have a history of chronic or acute pancreatitis.
  • Have any prior use of ixekizumab or tirzepatide.
  • Have a previous failure or intolerance to an interleukin 17 inhibitor (IL-17i) or glucagon-like peptide 1 (GLP-1) receptor agonists.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
281 participants (actual)

Study arms

  • Experimental
    Ixekizumab

    Ixekizumab administered subcutaneous (SC).

    Drug: Ixekizumab

  • Experimental
    Ixekizumab and Tirzepatide

    Ixekizumab concomitantly administered with tirzepatide SC.

    Drug: Ixekizumab · Drug: Tirzepatide

Interventions

  • Administered SC

    Also known as: LY2439821

  • Administered SC.

    Also known as: LY3298176

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and At Least 10% Weight Reduction

    PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease).Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI score compared to baseline.

    Time frame: Baseline to Week 36

Secondary outcomes

  1. Percentage of Participants Who Simultaneously Achieved PASI 75 and At Least 5% Weight Reduction

    PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored separately, and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease). Participants achieving PASI 75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.

    Time frame: Baseline to Week 36

  2. Percentage of Participants Achieving PASI 100

    PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (none) to 4 (very severe). Each area is scored separately, and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no psoriasis) to 72 (the most severe disease). Participants achieving PASI 100 were defined as having an improvement of at least 100% in the PASI scores compared to baseline.

    Time frame: Baseline to Week 36

  3. Percentage of Participants Achieving At Least 10% Weight Reduction

    Percentage of Participants Who Achieved at Least a 10% Weight Reduction

    Time frame: Baseline to Week 36

07

Study locations

72 sites
  • Total Skin & Beauty Dermatology Center, PC DBA Total Dermatology
    Birmingham, Alabama 35203, United States
  • Medical Dermatology Specialists
    Phoenix, Arizona 85006, United States
  • Scottsdale Clinical Trials
    Scottsdale, Arizona 85260, United States
  • Yuma Clinical Trials
    Yuma, Arizona 85365, United States
  • Johnson Dermatology
    Fort Smith, Arkansas 72916, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • First OC Dermatology Research Inc
    Fountain Valley, California 92708, United States
  • Avance Clinical Trials
    Laguna Niguel, California 92677, United States
  • Metropolis Dermatology
    Los Angeles, California 90017, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Northridge Clinical Trials
    Northridge, California 91325, United States
  • Cura Clinical Research - Oxnard
    Oxnard, California 93030, United States
  • Integrative Skin Science and Research - Location 2
    Sacramento, California 95815, United States
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
  • Life Clinical Trials
    Coral Springs, Florida 33071, United States
  • Alliance for Multispecialty Research, LLC
    Fort Myers, Florida 33912, United States
  • NeoClinical Research
    Hialeah, Florida 33016, United States
  • Skin Care Research
    Hollywood, Florida 33021, United States
  • Encore Medical Research
    Hollywood, Florida 33024, United States
  • Solutions Through Advanced Research
    Jacksonville, Florida 32256, United States
  • Deluxe Health Center
    Miami Lakes, Florida 33014, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Leading Edge Dermatology
    Plantation, Florida 33317, United States
  • International Clinical Research - Sanford
    Sanford, Florida 32771, United States
  • Nodal Medical Center
    Tampa, Florida 33607, United States
  • Palm Harbor Dermatology PA d/b/a TrueBlue Clinical Research
    Tampa, Florida 33609, United States
  • DeNova Research
    Chicago, Illinois 60602, United States
  • Oak Dermatology
    Naperville, Illinois 60563, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • The Indiana Clinical Trials Center, PC
    Plainfield, Indiana 46168, United States
  • Equity Medical - Bowling Green
    Bowling Green, Kentucky 42104, United States
  • DelRicht Research
    Baton Rouge, Louisiana 70809, United States
  • Care Access - Lake Charles (Bayou Pines)
    Lake Charles, Louisiana 70601, United States
  • Dermatology and Skin Cancer Specialists, LLC
    Rockville, Maryland 20850, United States
  • Lawrence J. Green, MD, LLC
    Rockville, Maryland 20850, United States
  • Great Lakes Research Group, Inc.
    Bay City, Michigan 48706, United States
  • The Derm Institute of West Michigan
    Caledonia, Michigan 49316, United States
  • MI Skin Innovations
    Northville, Michigan 48167, United States
  • Las Vegas Dermatology
    Las Vegas, Nevada 89144, United States
  • Skin Cancer and Dermatology Institute - Reno
    Reno, Nevada 89509, United States
  • ActivMed Practices & Research, LLC.
    Portsmouth, New Hampshire 03801, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • Care Access - Hoboken
    Hoboken, New Jersey 07030, United States
  • Equity Medical
    New York, New York 10023, United States
  • Mount Sinai Doctors - East 85th Street
    New York, New York 10028, United States
  • Onsite Clinical Solutions - Huntersville
    Huntersville, North Carolina 28078, United States
  • Red River Research Partners
    Fargo, North Dakota 58103, United States
  • Optima Research - Boardman
    Boardman, Ohio 44512, United States
  • Dermatologists of Southwest Ohio
    Mason, Ohio 45040, United States
  • Oregon Medical Research Center
    Portland, Oregon 97201, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Dermatology Associates of Plymouth Meeting
    Plymouth Meeting, Pennsylvania 19462, United States
  • Columbia Dermatology & Aesthetics
    Columbia, South Carolina 29212, United States
  • International Clinical Research - Tennessee LLC
    Murfreesboro, Tennessee 37130, United States
  • DelRicht Research - Thompson's Station
    Smyrna, Tennessee 37167, United States
  • Tekton Research - Westlake Drive
    Austin, Texas 78746, United States
  • Bellaire Dermatology Associates
    Bellaire, Texas 77401, United States
  • Modern Research Associates, PLLC
    Dallas, Texas 75231, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • Tanner Clinic
    Layton, Utah 84041, United States
  • Care Access - Arlington
    Arlington, Virginia 22206, United States
  • Care Access - Danville
    Danville, Virginia 24541, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23502, United States
  • Bellevue Dermatology Clinic
    Bellevue, Washington 98004, United States
  • Dermatology of Seattle
    Burien, Washington 98168, United States
  • SCB Research Center
    Bayamón, 00961, Puerto Rico
  • Office of Dr. Alma M. Cruz
    Carolina, 00985, Puerto Rico
  • GCM Medical Group, PSC - Hato Rey Site
    San Juan, 00917, Puerto Rico
  • Mindful Medical Research
    San Juan, 00918, Puerto Rico
08

References and documents

Publications

  • Lebwohl M, Blauvelt A, Kartman CE, Leatherwood C, Gordon KB, Sattar N, Puig L, Merola JF, Siu K, Wang R, Sun L, Leung A, Somani N, Rueda MJ, Cardoso A, Genovese MC, Armstrong AW, Strober B. Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial. JAMA Dermatol. 2026 Jul 1;162(7):709-719. doi: 10.1001/jamadermatol.2026.1753. PubMed 42139049 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Jan 2026, 15 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 15 months is close to that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2024
First posted
Sep 19, 2024
StartActual
Sep 30, 2024
Primary completionActual
Jan 8, 2026
CompletionActual
Jun 1, 2026
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06588283
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 30, 2024
Primary completion
Jan 8, 2026
Completion
Jun 1, 2026
Last update
Jun 17, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion